Esperion (NASDAQ: ESPR) Performance:
Shares of Esperion (NASDAQ: ESPR) have been recently spotted trading -86.28% off of the 52-week high price. On the other end, the stock has been noted -22.24% away from the low price over the last 52-weeks. 52 week range of the stock remained $ 6.97 – 39.49. Switching over to some distances from popular moving averages, we see that the stock has been recorded -43.71% away from the 50 day moving average and -70.61% away from the 200 day moving average. Moving closer, we can see that shares have been trading -38.26% off of the 20-day moving average. 479 employees work in the Company. It has market cap of $269.55M.
The Healthcare USA based company Esperion Therapeutics, Inc. moved with change of -39.58% to $5.42 with the total traded volume of 14078446 shares in recent session versus to an average volume of 1.33M. The stock was up in the 5 days activity 16.64%. The one month performance of stock was -13.00%. ESPR [NASD] shares are at -31.47% for the quarter and driving a -69.82% return over the course of the past year and is now at -65.50% since this point in 2018.
Right now ESPR [NASD] beta is 0.88. The average volatility for the week and month was at 12.91% 10.21% respectively. There are 26.45M shares outstanding and 26.26M shares are floated in market.”
Esperion (NASDAQ: ESPR) News Report
Esperion (NASDAQ: ESPR) announced the pricing of its previously announced underwritten public offering of 32,142,858 shares of its common stock and short-term warrants to purchase up to an aggregate of 32,142,858 shares of common stock. Each share of common stock is being sold together with one short-term warrant to purchase one share of common stock at a combined public offering price of $7.00 per share of common stock and accompanying warrant, less the underwriting discounts and commissions. The short-term warrants have an exercise price of $9.00 per share, are exercisable immediately, and will expire two years following the date of issuance.
H.C. Wainwright & Co. is acting as sole book-running manager for the offering.
In addition, Esperion has granted the underwriter a 30-day option to purchase up to an additional 4,821,428 shares of common stock and/or warrants to purchase up to an additional 4,821,428 shares of common stock at the public offering price, less the underwriting discounts and commissions.
All of the securities being sold in the offering are being offered by Esperion. The offering is expected to close on or about December 7, 2021, subject to satisfaction of customary closing conditions.